Clinical Experience with the Smeloff-Cutter Prosthesis: 1- to 12-Year Follow-up

Keyphrases

• Clinical Experience 100%
• Thromboembolism 100%
• Prosthesis 100%
• 12-month Follow-up 100%
• Cutter 100%
• Aortic Valve Replacement 66%
• Warfarin 66%
• Sodium 66%
• Aortic Stenosis 66%
• Aortic Regurgitation 66%
• Survivors 33%
• Consecutive Patients 33%
• Bleeding 33%
• Anticoagulants 33%
• Operative 33%
• Male Patients 33%
• Coumadin 33%
• Long-term Survival 33%
• Mitral Valve Repair 33%
• Major Morbidity 33%
• 30-day Mortality 33%
• Coronary Artery Bypass Grafting 33%
• Antiplatelet Agents 33%
• Functional Improvement 33%
• New York Heart Association Functional Class 33%
• Age at Operation 33%
• Preoperative Status 33%
• Subacute Bacterial Endocarditis 33%
• Mitral Commissurotomy 33%
• Perivalvular Leak 33%
• Dominant Lesion 33%

Medicine and Dentistry

• Thromboembolism 100%
• Warfarin 100%
• Prosthesis 100%
• Aortic Insufficiency 66%
• Aortic Valve Replacement 66%
• Aortic Stenosis 66%
• Bleeding 33%
• Anticoagulant 33%
• Long Term Survival 33%
• Mitral Valve Replacement 33%
• Coronary Artery Bypass Graft 33%
• New York Heart Association Class 33%
• Antiplatelet Drug 33%
• Subacute Bacterial Endocarditis 33%
• Mitral Valve Commissurotomy 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Thromboembolism 100%
• Warfarin 100%
• Aortic Stenosis 66%
• Aortic Regurgitation 66%
• Anticoagulant Agent 33%
• Bleeding 33%
• Long Term Survival 33%
• Antithrombocytic Agent 33%
• Subacute Endocarditis 33%